新型验证组织生物标志物增强局限性前列腺癌风险分层模型
本研究通过对公开前列腺癌转录组数据集进行计算机分析,筛选出113个预后基因,并在机构队列(n=92)中用NanoString nCounter技术评估前20个预后基因,进一步用免疫组化在机构队列(n=121)和EMpACT联盟独立验证队列(n=199)中验证前三个候选标志物。结果显示NCAPH、UBE2C和ZWINT高组织表达与更差的前列腺癌特异性生存相关,且这些标志物组合可改善D'Amico、CAPRA和Cambridge预后分组等标准风险分层模型。
要点
- NCAPH、UBE2C和ZWINT高组织表达被识别并验证为局限性前列腺癌的新预后风险因素。
- 免疫组化证实NCAPH和UBE2C染色与更差的前列腺癌特异性生存显著相关。
- 外部验证队列中NCAPH和ZWINT蛋白高表达与更短的无进展生存相关。
核心结论
- NCAPH、UBE2C和ZWINT高组织水平是临床局限性前列腺癌患者的新预后风险因素,使用这些标志物可改善常规风险估计模型。
研究设计与样本
- 对公开前列腺癌转录组数据集进行计算机分析,并在机构队列(n=92)中用NanoString nCounter技术评估前20个预后基因。
- 用免疫组化在机构队列(n=121)和EMpACT联盟独立验证队列(n=199)中进一步评估前三个候选标志物。
- 终点为前列腺癌特异性生存(CSS)和无进展生存(PFS)。
主要发现
- 计算机分析识别出113个预后基因,前20个基因中有7个在机构根治性前列腺切除(RPE)队列中的预后价值得到确认。
- 低CENPO、P2RX5、ABCC5表达以及高ASF1B、NCAPH、UBE2C和ZWINT基因表达与更短CSS相关。
- 免疫组化分析证实NCAPH和UBE2C染色与更差CSS之间存在显著关联。
- 在外部验证队列中,更高NCAPH和ZWINT蛋白表达与更短PFS相关。
- 新识别的组织蛋白标志物组合改善了D'Amico、CAPRA和Cambridge预后分组等标准风险分层模型。
临床怎么用
- 作者认为,NCAPH、UBE2C和ZWINT高组织水平可作为新型预后风险因素,其使用可改善常规风险估计模型。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Localized prostate cancer (PCa) is a largely heterogeneous disease regarding its clinical behavior. Current risk stratification relies on clinicopathological parameters and distinguishing between indolent and aggressive cases remains challenging. To improve risk stratification, we aimed to identify new prognostic markers for PCa. METHODS: We performed an in silico analysis on publicly available PCa transcriptome datasets. The top 20 prognostic genes were assessed in PCa tissue samples of our institutional cohort (n = 92) using the NanoString nCounter technology. The three most promising candidates were further assessed by immunohistochemistry (IHC) in an institutional (n = 121) and an independent validation cohort from the EMPACT consortium (n = 199). Cancer-specific survival (CSS) and progression-free survival (PFS) were used as endpoints. RESULTS: Our in silico analysis identified 113 prognostic genes. The prognostic values of seven of the top 20 genes were confirmed in our institutional radical prostatectomy (RPE) cohort. Low CENPO, P2RX5, ABCC5 as well as high ASF1B, NCAPH, UBE2C, and ZWINT gene expressions were associated with shorter CSS. IHC analysis confirmed the significant associations between NCAPH and UBE2C staining and worse CSS. In the external validation cohort, higher NCAPH and ZWINT protein expressions were associated with shorter PFS. The combination of the newly identified tissue protein markers improved standard risk stratification models, such as D'Amico, CAPRA, and Cambridge prognostic groups. CONCLUSIONS: We identified and validated high tissue levels of NCAPH, UBE2C, and ZWINT as novel prognostic risk factors in clinically localized PCa patients. The use of these markers can improve routinely used risk estimation models.
引用
- Olah C, Mairinger F, Wessolly M, et al. Enhancing risk stratification models in localized prostate cancer by novel validated tissue biomarkers. Prostate Cancer Prostatic Dis. 2024. PMID: 39543244. doi:10.1038/s41391-024-00918-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。